Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

methionine aminopeptidase 2 inhibitor M8891

A proprietary orally available inhibitor of methionine aminopeptidase 2 (MetAP2), which cleaves the amino-terminal methionine residue from nascent proteins, with potential antiangiogenic and antineoplastic activities. Upon administration, MetAP2 inhibitor M8891 inhibits MetAP2 aminopeptidase activity and impairs protein synthesis, which may lead to a decrease in endothelial cell proliferation. Decreased proliferation of endothelial cells results in reductions of both angiogenesis and the growth and spread of solid tumors that are dependent on new blood vessel formation. MetAP2, a metallopeptidase, is involved in promoting protein synthesis and endothelial cell proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:MetAP2 inhibitor M8891
Code name:M8891
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search